Through its participation in the Multilateral Pharmaceutical Merger Task Force, the Competition Bureau, with its counterparts in the U.S., the European Union and the U.K., is reviewing its approach to the analysis of pharmaceutical mergers.
Notice of consultation
From May 10 to June 25, 2021, the task force is seeking input from stakeholders to inform its review of a variety of issues related to mergers in the pharmaceutical industry, including:
- potential new or refreshed theories of harm;
- the evaluation of the effects of a merger on innovation; and
- potential remedies to resolve competition concerns.
The U.S. Federal Trade Commission, will collect submissions on behalf of the task force.
How to submit your views
The task force encourages stakeholders, including health policy experts, economists, attorneys, scientists, health care practitioners, academics, and consumers to share ideas that will lead to the development of future enforcement and policy efforts.
Interested parties can review the consultation questions and provide written comments to the U.S. FTC by following the instructions in its public request for comment.
For more information about the Bureau's participation in the task force or this consultation, interested parties may contact the Bureau at any time by submitting a request for information on the Bureau's website.
In the details of your request, please direct your question to the attention of the Multilateral Pharmaceutical Merger Task Force.